Piper Sandler Reiterates Buy Rating on GeneDx Holdings Corp. (WGS)
Piper Sandler maintains its buy rating on GeneDx Holdings Corp. with a price target of $63, a 8.26% downside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on GeneDx Holdings Corp. (WGS) with a price target of $63.
- Piper Sandler's $63 price target implies 8.26% downside from GeneDx Holdings Corp.'s ($WGS) current $68.67 share price.
- GeneDx shares traded around $55.42 on Tuesday, with a market cap of approximately $1.65 billion.
- Key insider transactions include CEO Katherine Stueland selling shares on June 16, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler has reiterated its buy rating on GeneDx Holdings Corp. (NasdaqGS: WGS) with a price target of $63. Analyst David Westenberg maintained the rating on June 23, 2026, as the stock traded around $55.42 on Tuesday.
Piper Sandler vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
GeneDx Holdings Corp. Stock Down 20.5%
Shares of NasdaqGS:WGS traded near $55.42 on Tuesday. GeneDx Holdings Corp. has a market capitalization of approximately $1.65 billion, a forward P/E ratio of 45.01, and a beta of 1.971. The stock's 52-week range has been between $32.21 and $170.87. It shows a 50-day moving average of $54.79 and a 200-day moving average of $99.42. The company's current ratio is 3.088, with a quick ratio of 2.825 and a debt-to-equity ratio of 66.185.
$WGS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
GeneDx Holdings Corp. reported revenue of about $442.7 million, reflecting a growth rate of 17.4%. However, the company is not yet profitable, with a net margin of -17.6% and a return on equity of -30.4%. The next earnings release is expected on July 28, 2026.
Insider Buying and Selling at GeneDx Holdings Corp.
On June 16, 2026, CEO Katherine Stueland sold 10,501 shares at an average price of $60.76. Additionally, CFO Kevin Feeley was involved in multiple transactions on the same day, selling 7,197 shares and buying 7,197 shares, with no price disclosed for the buy transaction.
Analysts Set New Price Targets
On June 23, 2026, Piper Sandler maintained its buy rating on GeneDx Holdings Corp. with a price target of $63. Other firms have also maintained buy ratings recently, including Canaccord Genuity and Wells Fargo, both with a $75 target set on May 5, 2026. The consensus rating is a strong buy, with a mean target price of $77 among nine analysts.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., headquartered in Stamford, Connecticut, is a genomics company that offers genetic testing services, focusing on pediatric and rare diseases. The company specializes in whole exome and genome sequencing and provides data and information services. GeneDx also develops an AI-based platform for next-generation sequencing analysis and clinical reporting. Led by CEO Kevin Feeley, the company employs approximately 1,300 people.
Bottom Line
Piper Sandler's reiterated buy rating on GeneDx Holdings highlights continued confidence in the company's growth potential. Investors keep a close watch on analyst ratings and insider transactions to gauge market sentiment. Remember, 13F filings and analyst reports reflect past activity and may not indicate current positions or future performance.
Get GeneDx Holdings Corp. alerts
New 13F filings, insider trades, and analyst moves on $WGS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.